WO2012068355A3 - Treating aortic aneurysm by modulating toll-like receptors - Google Patents

Treating aortic aneurysm by modulating toll-like receptors Download PDF

Info

Publication number
WO2012068355A3
WO2012068355A3 PCT/US2011/061158 US2011061158W WO2012068355A3 WO 2012068355 A3 WO2012068355 A3 WO 2012068355A3 US 2011061158 W US2011061158 W US 2011061158W WO 2012068355 A3 WO2012068355 A3 WO 2012068355A3
Authority
WO
WIPO (PCT)
Prior art keywords
aortic aneurysm
receptors
treating aortic
treating
methods
Prior art date
Application number
PCT/US2011/061158
Other languages
French (fr)
Other versions
WO2012068355A2 (en
Inventor
Jonas B. Galper
Original Assignee
Tufts Medical Center, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts Medical Center, Inc. filed Critical Tufts Medical Center, Inc.
Publication of WO2012068355A2 publication Critical patent/WO2012068355A2/en
Publication of WO2012068355A3 publication Critical patent/WO2012068355A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/329—Diseases of the aorta or its branches, e.g. aneurysms, aortic dissection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Methods for treating aortic aneurysm, such as abdominal aortic aneurysm (AAA), by either activating TLR2 signaling or suppressing TLR4 signaling and methods for diagnosing aortic aneurysm and assessing aortic aneurysm treatment efficacy in, e.g., a laboratory animal, based on the amount of an immune cell population such as the regulatory T cell population and/or the M1 and M2 macrophage populations. Also disclosed herein are pharmaceutical compositions for use in treating aortic aneurysm, the composition comprising a TLR2 agonist, a TLR4 antagonist, or a combination thereof.
PCT/US2011/061158 2010-11-18 2011-11-17 Treating aortic aneurysm by modulating toll-like receptors WO2012068355A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41503910P 2010-11-18 2010-11-18
US61/415,039 2010-11-18

Publications (2)

Publication Number Publication Date
WO2012068355A2 WO2012068355A2 (en) 2012-05-24
WO2012068355A3 true WO2012068355A3 (en) 2012-07-26

Family

ID=45217680

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/061158 WO2012068355A2 (en) 2010-11-18 2011-11-17 Treating aortic aneurysm by modulating toll-like receptors

Country Status (1)

Country Link
WO (1) WO2012068355A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109490540A (en) * 2017-09-13 2019-03-19 中国科学院上海药物研究所 Diagnosing and treating application of the Monocytes/Macrophages in Aortic injury

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074026A1 (en) * 2004-08-11 2006-04-06 Hazen Stanley L Therapeutic agents and methods for cardiovascular disease
WO2008013799A2 (en) * 2006-07-27 2008-01-31 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
EP2018872A1 (en) * 2006-04-20 2009-01-28 Takeda Pharmaceutical Company Limited Pharmaceutical product
US20090291061A1 (en) * 2008-05-21 2009-11-26 Riordan Neil H Stem cell therapy for blood vessel degeneration

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US7727974B2 (en) 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
CA2624087A1 (en) 2005-09-30 2007-04-12 Oklahoma Medical Research Foundation Regulation of tool-like receptors on stem cells
MX2011004674A (en) 2008-11-04 2011-05-25 Idera Pharmaceuticals Inc Modulation of toll-like receptor 4 expression by antisense oligonucleotides.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060074026A1 (en) * 2004-08-11 2006-04-06 Hazen Stanley L Therapeutic agents and methods for cardiovascular disease
EP2018872A1 (en) * 2006-04-20 2009-01-28 Takeda Pharmaceutical Company Limited Pharmaceutical product
WO2008013799A2 (en) * 2006-07-27 2008-01-31 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
US20090291061A1 (en) * 2008-05-21 2009-11-26 Riordan Neil H Stem cell therapy for blood vessel degeneration

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
KUWAHATA S ET AL: "High expression level of Toll-like receptor 2 on monocytes is an important risk factor for arteriosclerotic disease", ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, IE, vol. 209, no. 1, 1 March 2010 (2010-03-01), pages 248 - 254, XP026924721, ISSN: 0021-9150, [retrieved on 20090831], DOI: 10.1016/J.ATHEROSCLEROSIS.2009.08.046 *
MERSMANN JAN ET AL: "Preconditioning by toll-like receptor 2 agonist Pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury", CRITICAL CARE MEDICINE, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 38, no. 3, 1 March 2010 (2010-03-01), pages 903 - 909, XP009156556, ISSN: 1530-0293 *
OWENS A P ET AL: "MyD88 deficiency attenuates angiotensin II-induced abdominal aortic aneurysm formation independent of signaling through toll-like receptors 2 and 4", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 31, no. 12, 1 December 2011 (2011-12-01), pages 2813 - 2819, XP009156555, ISSN: 1079-5642, DOI: 10.1161/ATVBAHA.111.238642 *
OWENS A PHILLIP III ET AL: "Toll-like Receptor 4 Deficiency Attenuates Angiotensin II-Induced Atherosclerosis and Abdominal Aortic Aneurysms via a MyD88-dependent Mechanism", CIRCULATION, vol. 118, no. 18, Suppl. 2, October 2008 (2008-10-01), & 81ST ANNUAL SCIENTIFIC SESSION OF THE AMERICAN-HEART-ASSOCIATION; NEW ORLEANS, LA, USA; NOVEMBER 08 -12, 2008, pages S369, XP009156640, ISSN: 0009-7322 *
YEN HUIMIN ET AL: "Regression of Abdominal Aortic Aneurysms by Targeting Toll-Like Receptor 2", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 118, no. 18, Suppl.2, 1 October 2008 (2008-10-01), pages S303 - S304, XP009156543, ISSN: 0009-7322 *

Also Published As

Publication number Publication date
WO2012068355A2 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
EP2709520A4 (en) Devices, systems, and methods for assessing implants, organs, transplants, tissues, synthetic constructs, vascular grafts, and the like
UA112068C2 (en) GEL COMPOSITION
BRPI1009981A2 (en) systems, methods and compositions for optimizing tissue and cell enriched grafts
IN2012DN02177A (en)
IN2012DN02702A (en)
WO2011017350A3 (en) Compounds as lysophosphatidic acid receptor antagonists
MX2013004061A (en) Cyclosporin analogs.
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
MX2009006651A (en) Activin-actrii antagonists and uses for increasing red blood cell levels.
EP2569330A4 (en) Chlorotoxin variants, conjugates, and methods for their use
EA201170227A1 (en) ИМИДАЗОЛКАРБОКСАМИДЫ
BR112014015909A8 (en) composition
MX2012008039A (en) Pharmaceutical formulation for proteins.
IN2013DN02552A (en)
EP2571982A4 (en) Antigen specific tregs and related compositions, methods and systems
MX2013004062A (en) Cyclosporin analogs.
MX2012013855A (en) Oligo-benzamide compounds and their use.
MX2013004315A (en) Methods and compositions for modulating the wnt pathway.
MX369020B (en) Bone harvesting.
CY1119468T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING RISK
MX341642B (en) A sustained -release composition containing a melanocortin receptor ligand as the active ingredient.
WO2011091410A8 (en) Trpv4 antagonists
WO2011041701A3 (en) Inplantable contrast agents and methods
WO2012068355A3 (en) Treating aortic aneurysm by modulating toll-like receptors
FR3012814B1 (en) POLYMER COMPOSITION COMPRISING AND RELEASING AN ODORANT ACTIVE COMPOUND

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11793588

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11793588

Country of ref document: EP

Kind code of ref document: A2